Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection-Reply.

Cohen, Stuart H; Louie, Thomas J; McGovern, Barbara H

Cohen, Stuart H; Louie, Thomas J; McGovern, Barbara H.

Affiliation

Cohen SH; University of California, Davis.
Louie TJ; University of Calgary, Calgary, Alberta, Canada.
McGovern BH; Seres Therapeutics, Cambridge, Massachusetts.

JAMA ; 329(12): 1033-1034, 2023 03 28.

Article in En | MEDLINE | ID: mdl-36976280

Subject(s)

Clostridioides difficile; Clostridium Infections; Gastrointestinal Microbiome; Probiotics; Anti-Bacterial Agents/pharmacology; Anti-Bacterial Agents/therapeutic use; Clostridium Infections/microbiology; Clostridium Infections/therapy; Follow-Up Studies; Gastrointestinal Microbiome/drug effects; Probiotics/pharmacology; Probiotics/therapeutic use; Recurrence

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clostridioides difficile / Clostridium Infections / Probiotics / Gastrointestinal Microbiome Type of study: Observational_studies / Prognostic_studies Language: En Journal: JAMA Year: 2023 Type: Article

Fulltext

XML

PubMed Links

Search on Google